)
Visual
test
Adicet Bio
Adicet Bio (ACET) investor relations material
Adicet Bio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Strong enrollment momentum in Phase 1 autoimmune program for prula-cel, with clinical updates expected in 1H and 2H 2026.
Achieved FDA alignment for outpatient dosing of prula-cel in lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients.
Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer (mCRPC) planned for 3Q 2026, with enrollment to begin 4Q 2026 pending clearance.
Financial highlights
R&D expenses for Q4 2025 were $25.0M, up from $23.3M in Q4 2024, mainly due to higher CRO/CDMO costs.
G&A expenses for Q4 2025 were $6.9M, down from $7.5M in Q4 2024, due to lower rent and office expenses.
Net loss for Q4 2025 was $30.5M ($2.94/share), compared to $28.7M ($5.06/share) in Q4 2024.
Full-year 2025 net loss was $116.8M ($16.95/share), slightly improved from $117.1M ($21.33/share) in 2024.
Cash, cash equivalents, and short-term investments were $158.5M as of Dec 31, 2025, down from $176.3M a year earlier.
Outlook and guidance
Clinical update for prula-cel in LN, SLE, and SSc expected in 1H 2026, with another update in 2H 2026.
Pivotal study for prula-cel in LN or LN/SLE patients planned for 2H 2026, pending regulatory clearance.
Regulatory filing for ADI-212 in mCRPC planned for 3Q 2026; Phase 1 enrollment to begin 4Q 2026.
Cash runway expected to fund operations into the second half of 2027.
Outpatient dosing impact on pivotal trial design
MED12 disruption impact on ADI-212 potency
RA trial lymphodepletion regimen comparison
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Adicet Bio
- Prula-cel delivers steroid-free remissions and immune reset in autoimmune disease patients.ACET
Investor presentation12 Mar 2026 - Biotech seeks up to $250M for cell therapy pipeline, targeting autoimmune and cancer markets.ACETRegistration Filing12 Mar 2026
- Allogeneic Gamma-delta CAR-T therapies advance in autoimmune trials, with initial data imminent.ACETCanaccord Genuity’s 45th Annual Growth Conference3 Feb 2026
- Gamma delta CAR T therapies demonstrate promising safety, efficacy, and durability in autoimmune trials.ACETGuggenheim Securities 2nd Annual Healthcare Innovation Conference3 Feb 2026
- Allogeneic gamma delta CAR T cells advance in pivotal autoimmune and oncology trials, with key data ahead.ACETCanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026
- Off-the-shelf gamma delta T cell therapies advance in autoimmune and oncology, with pivotal data ahead.ACETJefferies 2024 Global Healthcare Conference1 Feb 2026
- Prioritizing autoimmune pipeline and advancing solid tumor program, with major data expected H1 next year.ACETH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Complete B-cell depletion and strong tissue trafficking set a new standard for cell therapy.ACET9th Annual CAR-TCR U.S. Summit20 Jan 2026
- Advancing off-the-shelf CAR gamma delta T cell therapies with key data readouts expected next year.ACETGuggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026
Next Adicet Bio earnings date
Q1 20266 May, 2026
Adicet Bio
Next Adicet Bio earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage